Jefferies Has Just Reaffirmed $88.1 Target Price Per Share on Parexel (NASDAQ:PRXL) stock, While They’ve Also Reiterated Their “Hold” Rating

September 17, 2017 - By Henry Gaston

 Jefferies Has Just Reaffirmed $88.1 Target Price Per Share on Parexel (NASDAQ:PRXL) stock, While They’ve Also Reiterated Their

Investors sentiment decreased to 0.85 in 2016 Q4. Its down 0.15, from 1 in 2016Q3. It dived, as 51 investors sold PAREXEL International Corporation shares while 100 reduced holdings. 46 funds opened positions while 83 raised stakes. 47.26 million shares or 0.12% more from 47.20 million shares in 2016Q3 were reported.

Trust Department Mb Bancshares N A owns 4,151 shares. Mason Street Advisors Lc has invested 0.04% in PAREXEL International Corporation (NASDAQ:PRXL). Bessemer Group Inc Inc stated it has 0.01% of its portfolio in PAREXEL International Corporation (NASDAQ:PRXL). Citigroup has 0% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 51,546 shares. Texas Permanent School Fund reported 38,850 shares or 0.03% of all its holdings. Amalgamated Fincl Bank reported 7,233 shares. Congress Asset Mngmt Company Ma holds 761,630 shares or 1.05% of its portfolio. Moreover, Panagora Asset Mngmt has 0% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 1,080 shares. Aqr Capital Ltd Liability owns 237,673 shares for 0.02% of their portfolio. Btim Corporation stated it has 337,266 shares. Northwestern Mutual Wealth Mngmt Company has 1,682 shares for 0% of their portfolio. Phocas Fincl Corp has 0.32% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 75,072 shares. King Luther Cap Corporation holds 34,863 shares. Blackrock Inv Mngmt Ltd holds 0.03% or 352,069 shares. Piermont Cap Mgmt Inc accumulated 0.21% or 13,890 shares.

Parexel (NASDAQ:PRXL) Rating Reaffirmed

In a research note made public this morning, Jefferies maintained their “Hold” rating on Parexel (NASDAQ:PRXL) shares. The target price gives a possible upside of 0.17 % from firm’s last stock close.

Investors sentiment decreased to 0.85 in 2016 Q4. Its down 0.15, from 1 in 2016Q3. It dived, as 51 investors sold PAREXEL International Corporation shares while 100 reduced holdings. 46 funds opened positions while 83 raised stakes. 47.26 million shares or 0.12% more from 47.20 million shares in 2016Q3 were reported.

Trust Department Mb Bancshares N A owns 4,151 shares. Mason Street Advisors Lc has invested 0.04% in PAREXEL International Corporation (NASDAQ:PRXL). Bessemer Group Inc Inc stated it has 0.01% of its portfolio in PAREXEL International Corporation (NASDAQ:PRXL). Citigroup has 0% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 51,546 shares. Texas Permanent School Fund reported 38,850 shares or 0.03% of all its holdings. Amalgamated Fincl Bank reported 7,233 shares. Congress Asset Mngmt Company Ma holds 761,630 shares or 1.05% of its portfolio. Moreover, Panagora Asset Mngmt has 0% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 1,080 shares. Aqr Capital Ltd Liability owns 237,673 shares for 0.02% of their portfolio. Btim Corporation stated it has 337,266 shares. Northwestern Mutual Wealth Mngmt Company has 1,682 shares for 0% of their portfolio. Phocas Fincl Corp has 0.32% invested in PAREXEL International Corporation (NASDAQ:PRXL) for 75,072 shares. King Luther Cap Corporation holds 34,863 shares. Blackrock Inv Mngmt Ltd holds 0.03% or 352,069 shares. Piermont Cap Mgmt Inc accumulated 0.21% or 13,890 shares.

PAREXEL International Corporation (NASDAQ:PRXL) Ratings Coverage

Among 17 analysts covering Parexel International (NASDAQ:PRXL), 1 have Buy rating, 3 Sell and 13 Hold. Therefore 6% are positive. Parexel International has $88.1000 highest and $49 lowest target. $70.64’s average target is -19.68% below currents $87.95 stock price. Parexel International had 38 analyst reports since August 7, 2015 according to SRatingsIntel. Avondale maintained the stock with “Underperform” rating in Monday, April 11 report. The firm earned “Buy” rating on Monday, March 28 by SunTrust. The rating was maintained by Jefferies with “Hold” on Monday, September 11. Deutsche Bank maintained it with “Hold” rating and $69.0 target in Friday, August 7 report. Robert W. Baird upgraded the shares of PRXL in report on Friday, October 9 to “Outperform” rating. The firm has “Hold” rating given on Tuesday, June 20 by Barclays Capital. The rating was maintained by Deutsche Bank on Friday, October 28 with “Hold”. The stock of PAREXEL International Corporation (NASDAQ:PRXL) earned “Neutral” rating by Robert W. Baird on Thursday, October 27. First Analysis downgraded PAREXEL International Corporation (NASDAQ:PRXL) rating on Thursday, November 17. First Analysis has “Equal-Weight” rating and $62 target. As per Friday, December 16, the company rating was downgraded by Goldman Sachs.

The stock increased 0.02% or $0.02 on September 15, reaching $87.95. About 798,422 shares traded or 13.22% up from the average. PAREXEL International Corporation (NASDAQ:PRXL) has risen 35.35% since September 17, 2016 and is uptrending. It has outperformed by 18.65% the S&P500.

Analysts await PAREXEL International Corporation (NASDAQ:PRXL) to report earnings on October, 25. They expect $0.89 earnings per share, up 17.11 % or $0.13 from last year’s $0.76 per share. PRXL’s profit will be $45.54 million for 24.71 P/E if the $0.89 EPS becomes a reality. After $1.02 actual earnings per share reported by PAREXEL International Corporation for the previous quarter, Wall Street now forecasts -12.75 % negative EPS growth.

PAREXEL International Corporation is a biopharmaceutical outsourcing services company. The company has market cap of $4.50 billion. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. It has a 42.82 P/E ratio. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).

More notable recent PAREXEL International Corporation (NASDAQ:PRXL) news were published by: Reuters.com which released: “Contract research firm Parexel International explores sale: sources” on May 08, 2017, also Businesswire.com with their article: “PAREXEL and Osaka International Cancer Institute Form Alliance to Advance …” published on August 21, 2017, Seekingalpha.com published: “Upside Potential From Possible Transaction At PAREXEL International” on May 25, 2017. More interesting news about PAREXEL International Corporation (NASDAQ:PRXL) were released by: Reuters.com and their article: “Pamplona Capital to take Parexel private for $4.5 billion” published on June 20, 2017 as well as Businesswire.com‘s news article titled: “PAREXEL International Reports Fourth Quarter and Fiscal Year 2017 Results” with publication date: August 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.